Sorrento Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SRNEQ research report →
Companywww.sorrentotherapeutics.com
Sorrento Therapeutics, Inc. , a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex.
- CEO
- Henry H. Ji
- IPO
- 2007
- Employees
- 949
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $16.54M
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.01
- EV/EBITDA
- -0.21
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 46.77%
- Op Margin
- -802.55%
- Net Margin
- -911.60%
- ROE
- -1904.94%
- ROIC
- -286.80%
Performance & Tape
- 52W High
- $0.42
- 52W Low
- $0.00
- 50D MA
- $0.02
- 200D MA
- $0.09
- Beta
- 2.29
- Avg Volume
- 329.98K
Get TickerSpark's AI analysis on SRNEQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SRNEQ Coverage
We haven't published any research on SRNEQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SRNEQ Report →